Severity assessment scores to guide empirical use of antibiotics in community acquired pneumonia

The Lancet Respiratory Medicine

Volumn 1, Issue 8, 2013, Pages 653-662

  Singanayagam, Aran ^a   Chalmers, James D ^b  

^a ST MARY S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOPENICILLIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; GENTAMICIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; TAZOBACTAM; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; BACTERIUM IDENTIFICATION; CEREBROVASCULAR DISEASE; CHLAMYDOPHILA PNEUMONIAE; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CORTICOSTEROID THERAPY; COXIELLA BURNETII; DIABETES MELLITUS; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG TREATMENT FAILURE; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HOSPITAL ADMISSION; HUMAN; INAPPROPRIATE PRESCRIBING; INFECTION RISK; INTENSIVE CARE UNIT; LEGIONELLA; LOW RISK POPULATION; MEDICAL SOCIETY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; MORAXELLA CATARRHALIS; MORTALITY; MYCOPLASMA PNEUMONIAE; NURSING HOME; PATHOGENESIS; PATIENT CARE; PATIENT SAFETY; PNEUMONIA; PNEUMONIA SEVERITY INDEX; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PSEUDOMONAS AERUGINOSA; RECEIVER OPERATING CHARACTERISTIC; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SEVERITY ASSESSMENT SCORE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; AMBULATORY CARE; COMMUNITY-ACQUIRED INFECTIONS; HOSPITALIZATION; MICROBIOLOGY; PNEUMONIA, BACTERIAL; SEVERITY OF ILLNESS INDEX;

AMBULATORY CARE; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; HOSPITALIZATION; HUMANS; PNEUMONIA, BACTERIAL; PRACTICE GUIDELINES AS TOPIC; SEVERITY OF ILLNESS INDEX;

EID: 84885034763     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(13)70084-5     Document Type: Review

References (75)

1. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009, 64(suppl 3):1-55.
2. Akram AR, Chalmers JD, Hill AT Predicting mortality with severity assessment tools in out-patients with community-acquired pneumonia. QJM 2011, 104:871-879.
3. Woodhead M, Welch CA, Harrison DA, Bellingan G, Ayres JG Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database. Crit Care 2006, 10(suppl 2):S1.
4. Tang CM, Macfarlane JT Early management of younger adults dying of community acquired pneumonia. Respir Med 1993, 87:289-294.
5. Neill AM, Martin IR, Weir R, et al. Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996, 51:1010-1016.
6. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections-full version. Clin Microbiol Infect 2011, 17(suppl 6):E1-59.
7. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(suppl 2):S27-S72.
8. Menendez R, Torres A, Aspa J, et al. Community Acquired Pneumonia. New guidelines of the spanish society of chest diseases and thoracic surgery (SEPAR). Arch Bronconeumol 2010, 46:543-558.
9. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. Can Respir J 2000, 11:237-248. Canadian Infectious Disease Society, Canadian Thoracic SocietyCanadian Thoracic Society.
10. Corréa Rde A, Lundgren FL, Pereira-Silva JL, et al. Brazilian guidelines for community-acquired pneumonia in immunocompetent adults - 2009. J Bras Pneumol 2009, 35:574-601.
11. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009, 64(suppl 3):iii1-ii55.
12. Therapeutic guidelines: antibiotic. Version 14 2010, Antibiotic Expert Group, Therapeutic Guidelines, Melbourne.
13. Yanagihara K, Kohno S, Matsusima T Japanese guidelines for the management of community-acquired pneumonia. Int J Antimicrob Agents 2001, 18(suppl):S45-S48.
14. Roson B, Carratala J, Fernandez-Sabe N, Tubau F, Manresa F, Gudiol F Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004, 164:502-508.
15. Chalmers JD, Al-Khairalla M, Short PM, Fardon TC, Winter JH Proposed changes to management of lower respiratory tract infections in response to the Clostridium difficile epidemic. J Antimicrob Chemother 2010, 65:608-618.
16. Wilcox MH Respiratory antibiotic use and Clostridium difficile infection: is it the drugs or is it the doctors?. Thorax 2000, 55:633-634.
17. Bewick T, Cooper VJ, Lim WS Does early review by a respiratory physician lead to a shorter length of stay for patients with non-severe community-acquired pneumonia?. Thorax 2009, 64:709-712.
18. Chalmers JD, Singanayagam A, Akram AR, Choudhury G, Mandal P, Hill AT Safety and efficacy of CURB65-guided antibiotic therapy in community-acquired pneumonia. J Antimicrob Chemother 2011, 66:416-423.
19. Gutierrez F, Masia M, Mirete C, et al. The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. J Infect 2006, 53:166-174.
20. Feldman C, Ross S, Mahomed AG, Omar J, Smith C The aetiology of severe community-acquired pneumonia and its impact on initial, empiric, antimicrobial chemotherapy. Respir Med 1995, 89:187-192.
21. Rello J, Bodi M, Mariscal D, et al. Microbiological testing and outcome of patients with severe community-acquired pneumonia. Chest 2003, 123:174-180.
22. Hoge CW, Reichler MR, Dominguez EA, et al. An epidemic of pneumococcal disease in an overcrowded, inadequately ventilated jail. N Engl J Med 1994, 331:643-648.
23. Nuorti JP, Butler JC, Farley MM, et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med 2000, 342:681-689.
24. Kofteridis D, Samonis G, Mantadakis E, et al. Lower respiratory tract infections caused by Haemophilus influenzae: clinical features and predictors of outcome. Med Sci Monit 2009, 15:CR135-CR139.
25. Woodhead MA, Macfarlane JT Comparative clinical and laboratory features of legionella with pneumococcal and mycoplasma pneumonias. Br J Dis Chest 1987, 81:133-139.
26. Marrie TJ, Costain N, La Scola B, et al. The role of atypical pathogens in community-acquired pneumonia. Semin Respir Crit Care Med 2012, 33:244-256.
27. Muscedere J, Ofner M, Kumar A, et al. The occurrence and impact of bacterial organisms complicating critical care illness associated with influenza A (H1N1) infection. Chest 2013, published online Feb 7. 10.1378/chest.12-1861.
28. Rubinstein E, Kollef MH, Nathwani D Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008, 46(suppl 5):S378-S385.
29. Marrie TJ, Garay JR, Weir E Legionellosis: Why should I test and report?. CMAJ 2010, 182:538-542.
30. Socan M, Kosmelj K, Marinic-Fiser N, Vidmar L A prediction model for community-acquired Chlamydia pneumoniae pneumonia in hospitalized patients. Infection 2004, 32:204-209.
31. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. Am J Respir Crit Care Med 2005, 172:1169-1227. American Thoracic Society, Centers for Disease Control and PreventionCenters for Disease Control and Prevention, Infectious Diseases Society of AmericaInfectious Diseases Society of America.
32. Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to Gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002, 162:1849-1858.
33. Bodi M, Rodriguez A, Sole-Violan J, et al. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin Infect Dis 2005, 41:1709-1716.
34. Shorr AF, Zilberberg MD, Reichley R, et al. Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Clin Infect Dis 2012, 54:193-198.
35. Aliberti S, Di Pasquale M, Zanaboni AM, et al. Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. Clin Infect Dis 2012, 54:470-478.
36. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005, 128:3854-3862.
37. Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother 2007, 51:3568-3573.
38. Chalmers JD, Taylor JK, Singanayagam A, et al. Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: a UK cohort study. Clin Infect Dis 2011, 53:107-113.
39. Venditti M, Falcone M, Corrao S, Licata G, Serra P Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. Ann Intern Med 2009, 150:19-26. for the Study Group of the Italian Society of Internal M.
40. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections-summary. Clin Microbiol Infect 2011, 17(suppl 6):1-24.
41. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. Can J Infect Dis 2000, 11:237-248.
42. Cilloniz C, Ewig S, Polverino E, et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 2011, 66:340-346.
43. Chalmers JD, Mandal P, Singanayagam A, et al. Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. Intensive Care Med 2011, 37:1409-1420.
44. Valencia M, Badia JR, Cavalcanti M, et al. Pneumonia severity index class V patients with community-acquired pneumonia: characteristics, outcomes, and value of severity scores. Chest 2007, 132:515-522.
45. Lujan M, Gallego M, Rello J Optimal therapy for severe pneumococcal community-acquired pneumonia. Intensive Care Med 2006, 32:971-980.
46. Stralin K, Olcen P, Tornqvist E, Holmberg H Definite, probable, and possible bacterial aetiologies of community-acquired pneumonia at different CRB-65 scores. Scand J Infect Dis 2010, 42:426-434.
47. Akram AR, Chalmers JD, Taylor JK, Rutherford J, Singanayagam A, Hill AT An evaluation of clinical stability criteria to predict hospital course in community-acquired pneumonia. Clin Microbiol Infect 2013, published online Feb 26. 10.1111/1469-0691.12173.
48. Roson B, Carratala J, Dorca J, Casanova A, Manresa F, Gudiol F Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Clin Infect Dis 2001, 33:158-165.
49. Woodhead MA, Macfarlane JT, McCracken JS, Rose DH, Finch RG Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987, 1:671-674.
50. Marrie TJ, Peeling RW, Fine MJ, Singer DE, Coley CM, Kapoor WN Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med 1996, 101:508-515.
51. Capelastegui A, Espana PP, Bilbao A, et al. Etiology of community-acquired pneumonia in a population-based study: link between etiology and patients characteristics, process-of-care, clinical evolution and outcomes. BMC Infect Dis 2012, 12:134.
52. Torres A, Rello J Update in community-acquired and nosocomial pneumonia 2009. Am J Respir Crit Care Med 2010, 181:782-787.
53. Chalmers JD, Singanayagam A, Akram AR, et al. Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis. Thorax 2010, 65:878-883.
54. Singanayagam A, Chalmers JD, Hill AT Severity assessment in community-acquired pneumonia: a review. QJM 2009, 102:379-388.
55. Chalmers JD, Akram AR, Hill AT Increasing outpatient treatment of mild community-acquired pneumonia: systematic review and meta-analysis. Eur Respir J 2011, 37:858-864.
56. Lim WS, Woodhead M, British Thoracic S British Thoracic Society adult community acquired pneumonia audit 2009/10. Thorax 2011, 66:548-549.
57. Majumdar SR, Eurich DT, Gamble JM, Senthilselvan A, Marrie TJ Oxygen saturations less than 92% are associated with major adverse events in outpatients with pneumonia: a population-based cohort study. Clin Infect Dis 2011, 52:325-331.
58. Sanz F, Restrepo MI, Fernandez E, et al. Hypoxemia adds to the CURB-65 pneumonia severity score in hospitalized patients with mild pneumonia. Respir Care 2011, 56:612-618.
59. Choudhury G, Chalmers JD, Mandal P, et al. Physician judgement is a crucial adjunct to pneumonia severity scores in low-risk patients. Eur Respir J 2011, 38:643-648.
60. Chalmers JD, Singanayagam A, Hill AT Predicting the need for mechanical ventilation and/or inotropic support for young adults admitted to the hospital with community-acquired pneumonia. Clin Infect Dis 2008, 47:1571-1574.
61. Chen JH, Chang SS, Liu JJ, et al. Comparison of clinical characteristics and performance of pneumonia severity score and CURB-65 among younger adults, elderly and very old subjects. Thorax 2010, 65:971-977.
62. el Moussaoui R, de Borgie CA, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ 2006, 332:1355.
63. Choudhury G, Mandal P, Singanayagam A, Akram AR, Chalmers JD, Hill AT Seven-day antibiotic courses have similar efficacy to prolonged courses in severe community-acquired pneumonia-a propensity-adjusted analysis. Clin Microbiol Infect 2011, 17:1852-1858.
64. Aliberti S, Blasi F, Zanaboni AM, et al. Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia. Eur Respir J 2010, 36:128-134.
65. Cilloniz C, Ewig S, Polverino E, et al. Community-acquired pneumonia in outpatients: aetiology and outcomes. Eur Respir J 2012, 40:931-938.
66. Falguera M, Sacristan O, Nogues A, et al. Nonsevere community-acquired pneumonia: correlation between cause and severity or comorbidity. Arch Intern Med 2001, 161:1866-1872.
67. Miyashita N, Fukano H, Mouri K, et al. Community-acquired pneumonia in Japan: a prospective ambulatory and hospitalized patient study. J Med Microbiol 2005, 54:395-400.
68. Almirall J, Boixeda R, Bolibar I, et al. Differences in the etiology of community-acquired pneumonia according to site of care: a population-based study. Respir Med 2007, 101:2168-2175.
69. Lim WS, Macfarlane JT, Boswell TC, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 2001, 56:296-301.
70. Singanayagam A, Singanayagam A, Chalmers JD Obesity is associated with improved survival in community-acquired pneumonia. Eur Respir J 2012, published online Dec 6. 10.1183/09031936.00115312.
71. Cilloniz C, Ewig S, Ferrer M, et al. Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis. Crit Care 2011, 15:R209.
72. von Baum H, Ewig S, Marre R, et al. Community-acquired Legionella pneumonia: new insights from the German competence network for community acquired pneumonia. Clin Infect Dis 2008, 46:1356-1364.
73. Arnold FW, Ramirez JA, McDonald LC, Xia EL Hospitalization for community-acquired pneumonia: the pneumonia severity index vs clinical judgment. Chest 2003, 124:121-124.
74. Barlow G, Nathwani D, Myers E, et al. Identifying barriers to the rapid administration of appropriate antibiotics in community-acquired pneumonia. J Antimicrob Chemother 2008, 61:442-451.
75. Lee RW, Lindstrom ST A teaching hospital's experience applying the Pneumonia Severity Index and antibiotic guidelines in the management of community-acquired pneumonia. Respirology 2007, 12:754-758.